Form 8-K

8-K — EXOZYMES INC.

Accession: 0001493152-26-030205

Filed: 2026-06-26

Period: 2026-06-25

CIK: 0002010788

SIC: 2836 (BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES))

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — form8-k.htm (Primary)

EX-99.1 (ex99-1.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: form8-k.htm · Sequence: 1

false

0002010788

2026-06-25

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

Current

Report Pursuant to Section 13 or 15(d) of

the

Securities Exchange Act of 1934

Date

of Report (Date of earliest event reported):

June

25, 2026

EXOZYMES

INC.

(Exact

name of registrant as specified in its charter)

Nevada

001-42204

83-4550057

(State

or other jurisdiction

incorporation)

(Commission

File

Number)

(I.R.S.

Employer

Identification

No.)

750

Royal Oaks Drive, Suite 106

Monrovia,

CA 91016

(Address

of principal executive offices and zip code)

Registrant’s

telephone number, including area code: (626) 415-1488

Check

the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of

the following provisions:

☐

Written communications

pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant

to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications

pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications

pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(b) of the Exchange Act:

Title

of each class

Trading

Symbol(s)

Name

of each exchange on which registered

Common Stock

EXOZ

Nasdaq Capital Market

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405

of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☒

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01

Regulation FD Disclosure

June 24, 2026, the Company issued a press release announcing that it was being awarded a $2 Million NIH grant to advance cannaboinoid

analogs for drug discovery.

The

information contained in this Item 7.01 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange

Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act, or the

Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01.

Financial Statements

and Exhibits.

(d)

Exhibits

Description

of Exhibit

99.1*

Press Release, dated June 24, 2026

104*

Cover Page Interactive

Data File (embedded within the Inline XBRL Document).

Filed herewith

SIGNATURES

Pursuant

to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by

the undersigned hereunto duly authorized.

Date:

June 25, 2026

EXOZYMES INC.

/s/

Fouad Nawaz

Fouad

Nawaz,

Vice

President, Finance

EX-99.1

Filename: ex99-1.htm · Sequence: 2

Exhibit

99.1

eXoZymes

Awarded $2 Million NIH Grant to Advance Cannabinoid Analogs for Drug Discovery

Award

allows eXoZymes to expand its portfolio of proprietary new-to-nature molecules and potential future pharmaceutical assets and validates

the Company’s ability to make rare cannabinoids and new cannabinoid-like molecules.

NIH-backed

work on the two-year grant is expected to begin on July 1, 2026, and represents the second biosolution in eXoZymes’ pipeline after

NCT advancing towards partnership and commercialization.

Total

non-dilutive funding awarded to eXoZymes is now almost $20 million, validating the scalable nature of the Company’s platform

LOS

ANGELES, CA – June 24, 2026 – eXoZymes Inc. (NASDAQ: EXOZ) – a pioneer of

AI-enhanced enzymes that enable scalable manufacturing of nutraceuticals and novel pharmaceuticals – today announced that it has

received a Notice of Award from the National Institute of General Medical Sciences (NIGMS) of the National Institutes of Health (NIH)

for a Phase IIB Small Business Innovation Research (SBIR) grant totaling $2,028,518.

The

NIH funded work is expected to begin July 1, 2026, and will support eXoZymes’ program to make rare cannabinoids and engineer cannabinoid

analogs, which are modified versions of cannabinoids designed for pharmaceutical evaluation.

The

grant comes as rare and minor cannabinoids are drawing broader commercial attention with the U.S. minor cannabinoids market forecasted

to grow from approximately $11.5 billion in 2023 to $33.3 billion by 2030, representing a compound annual growth rate of approximately

15%.

The

anticipated market growth can be attributed to a large and expanding body of research that shows the endocannabinoid system in humans

is an unusually broad range of receptors, pointing to wide-ranging potential for clinical benefit. Yet, most rare cannabinoids with therapeutic

potential occur in plants only in trace amounts, and seldom at the purity needed for meaningful commercialization. eXoZymes’ cell-free

platform is designed to produce these molecules outside living cells reliably, abundantly, and at high purity to then use as starting

points for new analogs that can have improved drug-like properties.

“The

hardest part of cannabinoid drug discovery has always been a supply and purity problem - the most interesting molecules are the ones

nature makes the least of. Our platform is built to change that. Once we can reliably produce the naturally occurring cannabinoids, we

can engineer new-to-nature analogs around them that are more potent and better suited to pharmaceutical drug development than what is

available today,” said Michael Heltzen, CEO of eXoZymes, and continues, “After the profound progress we have made

with NCT, this award demonstrates how our patented cell-free approach now adds a second biosolution to our pipeline and creates new

opportunities for pharmaceutical partners. This is a key milestone that demonstrates our repeatable development engine of future licensing

and partnering opportunities - a key feature in creating additional proprietary molecules without diluting shareholders.”

Under

the awarded program, eXoZymes will pursue three primary objectives:

Advanced

development of expression systems for cannabinoid cyclase enzymes.

Strategic

expansion of the range of analogs the company can produce.

Preclinical

evaluation of the Company’s existing cannabinoid library using established biological targets - receptor-binding assays - supported

by in-house scale capability.

“As

indicated by the high growth rate of the rare cannabinoids market, we are witnessing a transition from an industry built around cultivating

and extracting a handful of naturally abundant cannabinoids to one powered by biotechnology and molecular design,” said Tyler

Korman, PhD, co-founder and Chief Scientific Officer of eXoZymes and Principal Investigator on the award.

Korman

continues, “Rare cannabinoids show great promise, but researchers have been severely limited by supply. Our goal is to develop

proprietary enzyme-based manufacturing technologies designed to produce rare and novel plant-derived cannabinoids at pharmaceutical grade.

These capabilities can then lead to a pipeline of drug candidates targeting significant unmet medical needs and generate the preclinical

data required to advance them toward the clinic. This work is challenging and the NIH support helps us accelerate development with scientific

rigor to open up a much larger landscape of molecules that could become tomorrow’s medicines.”

The

grant, titled “SimplePath IIB: Pre-clinical Development of Cannabinoid Analogs” is funded through the National

Institute of General Medical Sciences (NIGMS) and includes $1,034,289 for the initial budget period and $994,229 for the second year,

subject to continued progress and funding availability. eXoZymes will serve as the prime award recipient, with co-founder and CSO Dr.

Tyler Korman serving as Principal Investigator. The program includes a sub-award to the laboratory of Dr. Vikram Shende at Occidental

College. The award brings total non-dilutive funding awarded to eXoZymes and its predecessor programs to $19.7 million.

Funding

Acknowledgment

Research

reported in this release was supported by the National Institute of General Medical Sciences of the National Institutes of Health under

Award Number R44GM159516. The content is solely the responsibility of the authors and does not necessarily represent the official views

of the National Institutes of Health.

About

eXoZymes

Founded

in 2019, eXoZymes is pioneering a cell-free biomanufacturing platform that uses AI-enhanced enzymes - called exozymes - to make valuable

natural products and new analogs outside living cells. The company’s platform is designed to replace inefficient extraction and

petrochemical processes with a scalable way to produce high-value molecules for nutraceutical and pharmaceutical markets.

eXoZymes

is building a portfolio of biosolutions across cannabinoid analogs, santalene and other high-value molecules, with potential commercialization

paths that include partnerships, licensing and joint ventures. Learn more at exozymes.com

eXoZymes

Safe Harbor

This

press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking

statements, which are based on certain assumptions and describe the company’s future plans, strategies and expectations, can generally

be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “will,”

“should,” “would,” “could,” “seek,” “intend,” “plan,” “goal,”

“project,” “estimate,” “anticipate,” “strategy,” “future,” “likely,”

“potential,” or other comparable terms, although not all forward-looking statements contain these identifying words. All

statements other than statements of historical facts included in this press release regarding the company’s strategies, prospects,

financial condition, operations, costs, plans and objectives are forward-looking statements. Actual results could differ materially for

a variety of reasons. You should carefully consider the risks and uncertainties described in the “Risk Factors” section of

eXoZymes’ quarterly reports on Form 10-Q, annual reports on Form 10-K, and other documents filed by eXoZymes from time to time

by the company with the Securities and Exchange Commission. These filings identify and address important risks and uncertainties that

could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements

speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and eXoZymes

assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information,

future events, or otherwise. eXoZymes does not give any assurance that it will achieve its expectations.

eXoZymes

contact

Lasse

Görlitz, VP of Comms & IR

(858)

319-7135

press@exozymes.com

| X | YouTube

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 7

v3.26.1

Cover

Jun. 25, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Jun. 25, 2026

Entity File Number

001-42204

Entity Registrant Name

EXOZYMES

INC.

Entity Central Index Key

0002010788

Entity Tax Identification Number

83-4550057

Entity Incorporation, State or Country Code

Entity Address, Address Line One

750

Royal Oaks Drive

Entity Address, Address Line Two

Suite 106

Entity Address, City or Town

Monrovia

Entity Address, State or Province

Entity Address, Postal Zip Code

91016

City Area Code

(626)

Local Phone Number

415-1488

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock

Trading Symbol

EXOZ

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

true

Elected Not To Use the Extended Transition Period

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration